Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT4 | P35916 | 14/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 2/20 | 0.39 |
| ▸ | NPR3 | P17342 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15513626 | 0.92 | FLT4 (0.46) | FLT4KDRMAPK1RPS6KA1BRAF | |
| SCHEMBL15513029 | 0.88 | FLT4 (0.52) | FLT4KDRMAPK1RPS6KA1PTK2 | |
| SCHEMBL15568784 | 0.85 | FLT4 (0.43) | FLT4KDRMAPK1RPS6KA1NPR3 | |
| SCHEMBL15524717 | 0.84 | FLT4 (0.44) | FLT4KDRMAPK1RPS6KA1BRAF | |
| SCHEMBL15512843 | 0.80 | FLT4 (0.62) | FLT4KDRMAPK1RPS6KA1NPR3 | |
| SCHEMBL15513472 | 0.79 | FLT4 (0.49) | FLT4KDRPTK2 | |
| SCHEMBL15568716 | 0.78 | FLT4 (0.43) | FLT4KDRMAPK1RPS6KA1NPR3 | |
| SCHEMBL15524515 | 0.77 | FLT4 (0.41) | FLT4MAPK1RPS6KA1BRAFNPR3 | |
| SCHEMBL15513211 | 0.77 | FLT4 (0.48) | FLT4KDRPTK2 | |
| SCHEMBL15513122 | 0.76 | FLT4 (0.50) | FLT4KDRPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160009686-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-14 | — | — | US | claimed |
| US-9238644-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-19 | — | — | US | disclosed |
| US-20160009686-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-14 | — | — | US | disclosed |
| EP-2885291-A1 | VEGFR3 INHIBITORS | Cancer Therapeutics Crc Pty Limited (AU) | 2015-06-24 | — | — | EP | disclosed |
| US-20140073620-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-13 | — | — | US | disclosed |
| WO-2014026243-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009686-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | FLT4 1/4885KDR 3/4885MAPK1 307/4885 |
| US-20140073620-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | FLT4 1/4885KDR 3/4885MAPK1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.